Health News
NIH publishes the largest genomic study on type 2 diabetes in sub-Saharan African populations
- Details
- Written by Prabarna Ganguly, Ph.D. Prabarna Ganguly, Ph.D.
- Published: 19 July 2019 19 July 2019
Washington, DC - National Institute of Health researchers have reported the largest genomic study of type 2 diabetes (T2D) in sub-Saharan Africans, with data from more than 5,000 individuals from Nigeria, Ghana and Kenya. Researchers confirmed known genomic variants and identified a novel gene ZRANB3, which may influence susceptibility to the disease in sub-Saharan African populations.
Executive Order on Advancing American Kidney Health
- Details
- Written by White House White House
- Published: 13 July 2019 13 July 2019
Washington, DC - By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered as follows:
Celebrity chefs could reduce foodborne illnesses
- Details
- Written by Maureen Manier Maureen Manier
- Published: 28 June 2019 28 June 2019
West Lafayette, Indiana - Foodborne illnesses sicken more than 48 million people in the United States each year, with 128,000 requiring hospitalization and 3,000 dying, according to the U.S. Centers for Disease Control and Prevention. Preparing food using thermometers correctly to ensure that it is cooked well enough to eliminate pathogens and bacteria could save some of those lives.
FDA seeks to advance safe and effective prostate tissue ablation devices
- Details
- Written by YNN YNN
- Published: 28 June 2019 28 June 2019
Washington, DC - Today, the FDA issued a draft guidance to provide recommendations for device manufacturers regarding the clinical testing that must be conducted in accordance with special controls for high intensity ultrasound systems for prostate tissue ablation devices regulated under the agency’s 510(k) premarket notification program.
Chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma
- Details
- Written by Amanda Turney Amanda Turney
- Published: 12 June 2019 12 June 2019
Washington, DC - The U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma.